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Abstract  
BACKGROUND: Pharmacists can play a decisive role in the management of ambulatory 
patients with depression who poorly adhere to antidepressant drugs. 
OBJECTIVE: To systematically evaluate the effectiveness of pharmacist care on improving 
adherence to antidepressants in depressed outpatients. 
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was 
conducted.  RCTs were identified through electronic databases (Medline, Central, ISI web of 
knowledge and CSIC database) from inception to April 2010, reference lists were checked and 
experts were consulted. RCTs that evaluated the impact of pharmacist interventions on improving 
adherence to antidepressants in depressed patients in an outpatient setting (community pharmacy 
or pharmacy service) were included. Methodological quality was assessed and methodological 
details and outcomes were extracted in duplicate.  
RESULTS: Six RCTs were identified. A total of 887 patients with an established diagnosis of 
depression who were initiating or maintaining pharmacological treatment with antidepressant 
drugs and who received pharmacist care (459 patients) or usual care (428 patients) were included 
in the review. The most commonly reported interventions were patient education and monitoring, 
monitoring and management of toxicity and side effects, compliance promotion, provision of 
written or visual information and recommendation or implementation of changes or adjustments 
in medication. Overall, no statistical heterogeneity or publication bias was detected. Pooled odds 
ratio, using a random effects model, was 1.64 (95% CI 1.24-2.17). Subgroup analysis showed no 
statistically significant differences in results by type of pharmacist involved, adherence measure, 
diagnostic tool or analysis strategy. 
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CONCLUSIONS: These results suggest that pharmacist intervention is effective in the 
improvement of adherence to antidepressants. However, data are still limited and we would 
recommend more research in this area, specifically outside the USA.
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Background 
Depression is a major health concern worldwide due to its high prevalence, patient impairment 
and cost.1-3 Since the first antidepressant was introduced in 19574,5, pharmacological treatment 
for depression has undergone a number of changes but it is still the first approach for treatment of 
moderate and severe depression.6 In spite of the efforts to improve side-effect profile and 
tolerability of medication, adherence to antidepressant drugs is still poor.7,8 
The pharmacist is one of the most accessible healthcare professionals9 and can play a decisive 
role in the management of ambulatory patients. Pharmaceutical care is described as “the 
responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve a patient’s quality of life” and it involves cooperation with patients and other 
professionals with the aim of producing specific therapeutic outcomes for the patient.10 In 
physical conditions such as heart failure, asthma, diabetes, hypertension and dyslipidemia, 
pharmacist interventions have been shown to improve patient wellbeing in terms of clinical 
improvement and adherence.11-15  
Recently, pharmacists’ involvement in the management of patients suffering from mental health 
disorders has been increasing and studies have been carried out to evaluate the impact of 
pharmacist interventions in this population. In 2003, Finley et al.16 conducted a systematic review 
examining the impact of clinical pharmacists on the care and outcomes of patients with mental 
disorders including, among other diagnoses, schizophrenia, depression and behavioural 
disturbances. The pharmacist interventions described in the review included drug monitoring, 
treatment recommendations, patient education, drug management and education to providers on 
prescribing patterns. The results of this work indicated a positive effect of pharmacist 
interventions in patients with mental health problems, although there were several sources of 
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heterogeneity relating to the study design, patient populations, measured outcomes and treatment 
settings. Furthermore, since this review was published, more research has been conducted on this 
issue so these results would need to be updated. 
More recent systematic reviews have shown that multidisciplinary strategies for the management 
of patients with mental health problems in primary care have a positive effect on antidepressant 
use and depressive outcomes.17-19 These studies concluded that interventions conducted by case 
managers with a specific mental health background were more effective in improving symptom 
outcomes than those conducted by case managers without a specific mental health background, 
such as pharmacists. However, no differences were detected when the outcome assessed was 
antidepressant use. Furthermore, in these analyses pharmacists were grouped with other health 
professionals so their specific contribution to the results is difficult to determine. Overall, most of 
the literature in this field appeared not to show statistically significant differences between 
intervention and control groups and seemed to be inconclusive. We therefore conducted a meta-
analysis to increase the power of the study and to try to improve effect size estimate. 
In general, interventions conducted by pharmacists are usually focused on medication and, 
consequently, adherence to medication is the primary outcome in most of these studies. For this 
reason we decided to focus our review on adherence improvement. Furthermore, in patients with 
depression, it has been stated that there is a significant positive association between 
antidepressant use and improved depression outcomes.17,18 
The objective of this study is to systematically review randomized controlled trials (RCTs) 
evaluating the impact of pharmacist interventions on outpatients with regard to improvement of 
adherence to antidepressants when treating a depressive disorder. 
 
Methods 
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We followed the PRISMA guidelines for reporting meta-analysis.20 
 
Literature search 
We performed a systematic review of the published literature for RCTs evaluating the impact of 
pharmacist interventions on the improvement of adherence to antidepressant pharmacological 
treatment of outpatients with depressive disorder (major depressive disorder and dysthymic 
disorder) according to DSM (Diagnostic and Statistical Manual of Mental Disorders) or ICD 
(International Classification of Diseases) criteria. In order to identify all articles involving 
interventions intended to improve use of antidepressants, the databases were searched separately 
by two investigators (AFS and MRV). Literature searches were completed from inception to 
April 2010, without language restrictions, through Medline, the Cochrane Central Register of 
Controlled Trials database, the Institute for Scientific Information (ISI), and the Spanish National 
Research Council (CSIC) databases. 
The search strategy used was: [("Pharmaceutical Services"[Mesh] OR pharmac* OR 
"pharmaceutical intervention" OR "pharmacy counsel*" OR "pharmacy-based coaching") AND 
("Depressive Disorder"[Mesh] OR "depression" OR "Antidepressive Agents"[Mesh] OR 
"antidepressant*") AND ("Patient Compliance"[Mesh] OR "Treatment Refusal"[Mesh] OR 
"Patient Dropouts"[Mesh] OR adherence OR dropout OR compliance)]. 
Abstracts of all citations were obtained for study selection. Citation indices and reference lists of 
retrieved articles were checked for additional studies not identified in the original database 
search. Expert informants from the pharmaceutical industry and the School of Pharmacy 
(University of Barcelona) were consulted to retrieve grey literature (such as unpublished reports 
and conference abstracts).  
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Study selection 
Studies were screened for inclusion by reviewing the title, the published abstract, and the full 
article where necessary. First selection was made in duplicate (A.F.S. and M.R.V.). The final 
screening, which reviewed full text articles, was done by two researchers (A.S.B. and M.R.V.). 
One of the researchers (A.S.B.) was blind for the authors of the articles and the journals in which 
they were published. In the case of disagreement, a third researcher (A.F.S.) was consulted. 
We included RCTs with ambulatory patients diagnosed using a validated psychiatric interview or 
a clinical diagnosis for a mood disorder, and initiating or maintaining treatment with 
antidepressants. No restriction by type of antidepressant medication was applied. Nor were 
restrictions imposed with respect to age, gender or ethnicity. Interventions taken into account 
included educational messages and counseling, monitoring and medication dosage-adjustment, 
and management of adverse effects. Our definition of intervention excluded all research in which 
the pharmacist’s role was only focused on the review of medication patterns (i.e., detection of 
medication related problems, such as drug interactions, without a subsequent intervention 
delivered to the patient to solve the problems). As the intervention should be applied directly to 
the patient, articles evaluating the effect of pharmacist intervention in institutions, doctors or 
families were excluded. Articles were rejected if the study was conducted in an acute inpatient 
facility or hospital, or if it was a multidisciplinary model in which the role of the pharmacist was 
not well established. Nevertheless, there was no restriction regarding the setting where the 
intervention was done, so that community pharmacies or pharmacy services in hospitals or 
primary care centers were included. Regarding outcome measures, any measure evaluating 
adherence to medication was accepted: pharmacy records, electronic pill-container and self-
reported adherence. 
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Quality assessment 
The quality of the studies was assessed independently by Y.L.H. and M.R.V. using the Jadad 
scale.21 The Jadad scale is a three-item scale that considers three features of a study; 
randomization, double-blinding and flow of patients. Adequate description of allocation 
concealment was also evaluated so total summed scores range from 0 to 7, with the higher scores 
indicating higher quality.22-24 However, blinding of pharmacists and participants was not possible 
because of the type of intervention assessed in this meta-analysis so finally total scores ranged 
from 0 to 5. Inter-reviewer reliability for the quality of studies was measured by Kappa statistics 
(0.958). 
 
Data abstraction and quantitative data synthesis 
By using a standardized abstraction form, two reviewers (M.R.V. and Y.L.H.) independently 
extracted key features of the characteristics, methods and outcomes of articles that met the 
inclusion criteria. Key features included: study design, period of study, setting, sample size, 
number of pharmacists, intervention components, the main outcome measures reported by the 
authors and results and analysis strategy (i.e., per-protocol or intent-to-treat). In the case of 
disagreement, a third reviewer (J.G.C.) also checked the data and agreement was reached. Inter-
reviewer reliability was measured by Kappa statistics (0.910). 
Dichotomous and continuous measures of the outcome were extracted. For continuous data the 
standardized mean difference (SMD) was computed with 95% confidence interval (CI). Random 
effects model was used to calculate pooled odds ratios and 95% confidence interval. Statistical 
heterogeneity was assessed employing the Cochran's Q test and I-squared statistic. Publication 
bias was assessed using the funnel plot and Egger’s test.  
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In order to assess the possible effects of clinical heterogeneity in the meta-analysis results, 
subgroup analyses were performed according to setting of pharmacist doing the intervention 
(community pharmacies or pharmacy services in hospitals or primary care centers), main 
adherence measure (pharmacy records, electronic pill-container or self-reported adherence), and 
type of diagnosis used for inclusion (only clinical or with a validated diagnostic instrument). 
Those subgroup analyses were pre-specified. Moreover, subgroup analyses were performed 
according to the analysis strategy (intent-to-treat or per-protocol) as a means of assessing its 
effect in the results of the meta-analysis. 
Analyses were performed using Comprehensive Meta-analysis, version 2 (Biostat, Englewook, 
NJ, USA).  
 
Results 
Literature search and study selection 
The electronic search strategy identified 438 potentially relevant papers, while 7 additional 
studies were retrieved via the manual search of citation indices and reference lists. In all, 43 were 
duplicated titles indexed in multiple databases and were excluded. Of the 395 remaining studies, 
367 were excluded by reviewing title and abstract (221 described other interventions, the 
population in 78 were not depressed patients, 63 were not RCTs and 5 did not evaluate 
adherence) and 22 were excluded by reviewing full-text articles (7 did not evaluate compliance, 7 
were not RCTs, 6 described other interventions and 2 were only descriptive) (Figure 1).  
Correspondence was conducted with the corresponding author of one article describing study 
methods which matched the criteria for selection. Results at 6-month follow-up were published 
but no results were reported from that moment on.25 Even though we received an answer from the 
author, data was unavailable in this case. 
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- Insert Figure 1 - 
 
Characteristics and methodological quality of the included studies 
 
- Insert Table 1 – 
 
We identified 6 studies for inclusion in the analysis26-31 which assessed pharmacist interventions 
in patients initiating or maintaining a treatment with antidepressant medication (Table 1). 
Overall, 1049 subjects were randomized, 527 (50.2%) of whom were randomized to an 
intervention group and 522 (49.8%) to a control group. However, because of per-protocol 
analyses in some studies, results are reported for only 887 patients (84.9% of randomized 
patients), 459 (51.7%) belonging to the intervention group and 428 (48.3%) to the control group. 
Most of the studies (4 out of 6) were carried out in the USA26-28,30 while there was one European 
study29, performed in the Netherlands, and one study conducted in Australia.31 The studies were 
carried out between 1998 and 2005 and the publication years ranged from 2003 to 2006. There 
were no baseline significant differences in sociodemographic characteristics between the control 
and intervention groups. However, in three of the studies baseline differences related to 
antidepressant medication27,30 and clinical characteristics28 were reported. In the study by Rickles 
et al.30, intervention participants were more likely than control participants to have a history of 
psychotropic medication use (41.9% vs 15.6%; P<0.05). In the study by Adler et al.27, 
intervention participants were more likely to have first used antidepressants more than a year 
before the initial questionnaire (56.1% vs. 45.2%; P<0.05). Finally, in the study by Capoccia et 
al.28, more patients in the intervention group had been diagnosed with major depression at 
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baseline than in the control group (21% vs. 9%; P<0.05). However, in the case of the articles by 
Adler et al.27 and Capoccia et al.28, statistical analyses were controlled for prior experience with 
antidepressants and baseline SCID score respectively to minimize bias.  
All patients had an established diagnosis of depression and were initiating [n=658 (74.2 %)] or 
maintaining [n=229 (25.8%)] pharmacological treatment with antidepressant drugs. In the study 
by Brook et al.29, only patients taking nontricyclic antidepressants were considered for inclusion 
and in the study by Finley et al.26, 96% and 88% of control and intervention patients respectively 
were prescribed selective serotonin reuptake inhibitors. A total of 3 different methods of 
assessing adherence to antidepressants were defined; self-reported adherence (n=5)26-28,30,31, 
pharmacy records (n=4)26,27,29,30 and electronic pill-container (n=1).29 
In 3 of the 6 studies27,28,30, depression was diagnosed by means of validated diagnostic 
instruments based on DSM-IV criteria including the Primary Care Screener for Affective 
Disorders (PC-SAD), the Primary Care Evaluation of Mental Disorders (PRIME-MD) and the 
Beck Depression Inventory II (BDI-II). Baseline severity of depression was reported as being 
moderate to severe based on different measures (Beck Depression Inventory; Hopkins Symptom 
Checklist, Brief depression inventory and K10). 
While the follow-up period ranged from 2 to 12 months, in 4 of the studies it was 6 
months.26,27,29,30 Where possible, data from 6 months was used to perform the analysis (n=5).26-30 
Community pharmacists applied the intervention in 3 of the studies29-31, and pharmacists from a 
pharmacy service of a primary care setting performed it in the other 3 studies.26-28 
In one case29, information about the intervention was extracted from a previous publication 
related to the study.32 In all 6 studies the intervention included patient education and monitoring. 
Other common interventions were monitoring and management of toxicity and side effects 
(n=5)26-30, adherence promotion (n=4)26,27,30,31 and provision of written or visual information 
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(n=3).26,29,31 In two of the studies26,28, in which the intervention was conducted by a clinical 
pharmacist, the pharmacist could recommend or conduct changes or adjustments in medication. 
Methodological quality ranged from 2 to 5 on the Jadad scale, and 4 of the studies scored 3 or 
more.26,27,29,30 The most commonly absent item was an adequate description of concealment of 
allocation. 
Intent-to-treat analyses were conducted in 3 of the 6 studies.26,28,29 In the study by Adler et al.27, it 
is stated that an intent-to-treat analysis was conducted. However, not all randomized patients 
were included in the analysis, only those with any 6-month data. That is to say, 533 patients were 
randomized but information was only given for the 384 that completed the 6-month assessment. 
According to CONSORT guidelines33, in order to preserve fully the huge benefit of 
randomization, intent-to-treat analysis should include all randomized participants in the analysis, 
all retained in the group to which they were allocated. Using this conservative definition of the 
intent-to-treat approximation analysis, we decided to classify the Adler et al.27 study in the group 
of studies that conducted per-protocol analysis.27,30,31 
In 2 of the studies, some of the included patients were already on antidepressants at the time of 
enrolment.27,31 The study by Adler et al.27 reported results of patients initiating and maintaining 
treatment with antidepressants at the time of enrolment, while in the study by Crockett et al.31 this 
information was presented in aggregated form and it was not possible to discern who was being 
initiated or maintained on medication. For the present meta-analysis, results from all patients 
were included, regardless of whether patients were initiating or maintaining pharmacological 
treatment. In the study by Capoccia et al.28, compliance information at 6-months of follow-up 
was used. In the study by Finley et al.26, two different ways of reporting adherence were 
employed: the Mean Possession Ratio and the percentages of compliant patients. In the meta-
analysis, the information about the percentage of compliant patients at 6 months was used. 
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Meta-analysis 
 
- Insert Figure 2 - 
 
No significant heterogeneity was found between the included studies (Q=2.677; 5 df; P=0.750; I-
squared<0.001; Tau-squared<0.001). Pooled odds ratio demonstrated a significant benefit from 
pharmacist interventions in the improvement of adherence to antidepressant pharmacological 
treatment (1.639; 95% confidence interval 1.236 to 2.174; P<0.001) (Figure 2). 
When we compared the effectiveness of pharmacist intervention in depressed patients, after 
grouping by type of pharmacist implementing the intervention (community pharmacy or 
pharmacy service), type of diagnosis (clinical or validated psychiatric instrument), type of 
adherence measure (pharmacy records, electronic pill-container or self-reported) and analysis 
strategy (per-protocol or intent-to-treat), we observed that there are no significant differences as 
confidence intervals from different subgroups clearly overlapped (Figure 3). 
 
- Insert Figure 3 - 
 
The funnel plot of standard error against the natural logarithm of the odds ratio (Figure 4) and the 
Egger test for assessing bias (P=0.460) suggested that there was little publication bias in the 
selection of studies. 
 
- Insert Figure 4 - 
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The effect of removing one study in turn was assessed and showed that statistically significant 
results do not depend on any of the individual studies. Cumulative meta-analysis was also 
performed proving that the pooled estimate is robust over time. 
 
Discussion 
The results of the present meta-analysis suggest a positive effect of pharmacist interventions on 
antidepressant use in terms of adherence. These results are similar to those reported on 
collaborative care by Bower et al.17 that found a positive effect of collaborative care on adherence 
to antidepressants (OR=1.92; 95% CI 1.54-2.39). Subgroup analysis showed no significant 
differences between groups when grouping by type of pharmacist conducting the intervention, 
type of diagnostic procedure, type of adherence measure or analysis strategy used. 
These results should be interpreted with the following limitations in mind. Firstly, although a 
significant improvement in adherence to antidepressant medication was identified, it is unclear 
whether this will result in an improvement in depressive symptoms. However, previous studies 
have reported a positive association between improved antidepressant use and depressive 
symptoms suggesting that the effects of collaborative care on symptoms of depression may be 
mediated through changes in adherence to antidepressants.17,18 
Secondly, the RCTs included were different in some methodological approaches, such as setting 
of pharmacist performing the intervention, type of intervention performed and type of diagnostic 
measures. In this respect, studies considering different outcome measures were used, which could 
limit internal validity. Although no statistical heterogeneity was detected, Cochran's Q test has 
low power when the number of studies included in the meta-analysis is small and the I-squared 
statistic also suffers from large uncertainty in this situation. 
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In a similar way, the power of the Egger test for assessing bias can also be affected by the low 
number of studies included.  
Thirdly, a 6-month follow-up period is a short time if we are referring to antidepressant 
treatment, which should be continued for at least 6 months after remission of an episode of 
depression.6 However, it is well known that drop-out occurs mostly at the beginning of treatment 
with antidepressants.7 Even though a short follow-up period could have influenced the effect 
sizes of pharmacist intervention versus controls, the 2 month trial by Crockett et al.30 did not 
happen to alter the results, as we confirmed in the robustness of analysis. 
Fourthly, it should also be noted that most studies were conducted in the USA and the results 
may not generalize to other contexts. Finally, some baseline differences of the compared groups 
were identified in 3 of the studies27,28,30 which could introduce bias. However, in 2 of these 
studies27,28 statistical methods to adjust for the baseline differences were used to minimize bias 
while the third one30 reached the highest score on the Jadad scale and described an adequate 
randomization process and allocation concealment.  
In spite of these limitations, this study is, to the best of our knowledge, the first published 
systematic review and meta-analysis of pharmacist intervention in depressed patients. Analysis 
proved that the pooled estimate was robust and suggested that there was little publication bias.  
 
Conclusion 
The present review indicates that pharmacists’ interventions in the care of outpatients treated with 
antidepressants can significantly improve adherence to medication. Patient education and 
monitoring, along with monitoring and management of side effects and compliance promotion 
were the most commonly reported interventions in both pharmacy service and community 
pharmacy. Two of the studies conducted in a pharmacy service also allowed pharmacists to 
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recommend or conduct changes or adjustments in medication. However, no significant 
differences were found in terms of improvement of adherence to antidepressants when subgroup 
analyses were conducted by setting of pharmacist involved in the intervention.  
The present review indicates that the data generated from the published RCTs on pharmacist 
interventions in depressed patients are still limited. Only 6 studies have been identified, implying 
that the power of some of the statistics used may be limited and it is possible that we have not 
been able to detect existent heterogeneity between studies or publication bias. As such, we would 
recommend more research in this area, mainly outside the USA, to provide definite answers to 
the question we explored. 
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Table 1. Characteristics of included studies 
 Country Setting 
(number of 
pharmacists
) 
Key components of pharmacist 
intervention 
Main adherence 
measure (other 
adherence 
measures) 
Main diagnostic 
procedure  
Baseline 
level of 
depression by 
group 
(Measuremen
t tool) 
Main 
analysis 
strategy 
Randomized 
Patients (N) 
Number of 
women (%) 
Mean 
age 
Follow-up 
(months)  
Quality 
Finley et 
al. 
(2003)26 
USA PS (2) Medication education, 
depression education, 
adherence promotion, obtaining 
patient clinical history, 
monitoring drug efficacy and 
toxicity, recommendation for 
changes in medication to the 
physician, advising about other 
available treatment options, 
providing written information. 
Pharmacy 
records (Self-
reported) 
Clinical I=18.7 
C=18.3 
(BIDS) 
ITT 125 (I=75 
C=50) 
106 (85%) 54 6 4 
Adler et 
al. 
(2004)27 
USA PS (5) Medication education, 
depression education, 
adherence promotion, obtaining 
patient medication history, 
monitoring drug efficacy and 
toxicity, facilitating 
communication with the 
physician. 
Self-reported 
(Pharmacy 
records) 
VDI I=23.2 
C=23.2 
(mBDI) 
PP 384c,d (I=202 
C=182) 
364 (72%)g 42g 6 5 
28 
 
 
 
Capoccia 
et al. 
(2004)28 
USA PS (2) Medication education, 
depression education, 
adjustment of medication 
dosage and time of dose, 
change or discontinuation of 
antidepressants, monitoring and 
management of side effects, 
provision of medication refill 
authorizations, facilitating the 
access to patient assistance 
programs and appointments 
with mental health service 
providers. 
Self-reported VDI I=1.83 
C=1.75 
(SCL-20) 
ITT 74 (I=41 
C=33) 
42 (57%) 39 12 2 
Brook et 
al. 
(2005)29 
Netherlan
ds 
CP (19) Medication education, 
depression education, 
adherence promotion, 
monitoring and management of 
side effects, providing written 
and visual informationb. 
Electronic pill 
container 
(pharmacy 
records) 
Clinical I=3.1 C=2.8 
(SCL-13)b 
ITT 135 (I=64 
C=71) 
95 (70%) 43 6 3 
Rickles 
et al. 
(2005)30 
USA CP (14) Medication education, 
depression education, 
adherence promotion, 
monitoring and management of 
side effects, contact with 
prescriber if needed, 
Pharmacy 
records (Self-
reported) 
VDI I=28.9 
C=27.0 
(BDI-II) 
PP 63 (I=31 
C=32) 
53 (84%) 38 6 5 
29 
 
 
 
monitoring patient progress. 
Crockett 
et al. 
(2006)31 
Australia CP (32a) Medication education, 
monitoring patient progress, 
providing written and visual 
information. 
 
Self-reported Clinical I=23.0 
C=21.7 
(K10) 
PP 106e,f (I=46 
C=60) 
84 (79%)e 46e 2 2 
Abbreviations: PS=Pharmacy Service; CP=Community Pharmacy; VDI=Validated diagnosis instrument; I=Intervention; C=Control; 
N=Sample size; BIDS=Brief Inventory for Depressive Symptoms (range 0–42); mBDI=modified Beck Depression Inventory (range 0-
63); SCL-20=20-item Hopkins Symptom Checklist (range 0-4); SCL-13=13-item Hopkins Symptom Checklist (range 1-5); BDI-
II=Beck Depression Inventory (range 0-63); K10=10-question screening scale of psychological distress (range 10-50); ITT=Intent-to-
treat; PP=Per-protocol. 
a Number of pharmacies, number of pharmacists was not reported. b Data extracted from Brook OH et al. (2003)32. c 234 of the 
randomized patients were initiating treatment with antidepressants and 150 were already taking antidepressants at the time of 
inclusion. d 533 patients (I=265 C=268) were randomized but information was given only for the 384 that completed the 6-month 
assessment. e 119 (I=51 C=68) patients were randomized but results were reported for the 106 patients that completed the 2-month 
assessment. f 27 patients had been on antidepressant medication for less than one month at the beginning of the study. g Information 
from the 507 patients that completed the initial intervention. 
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Figure legends 
Figure 1. Flow diagram of studies screened, assessed for eligibility and included in the review 
RCT = Randomized Controlled Trial. 
 
Figure 2. Meta-analytic results 
 
Figure 3. Subgroup analyses by setting of pharmacist implementing the intervention, type of 
diagnosis, main of adherence measure and strategy of analysis 
VPI=Validated psychiatric instrument; EPC=Electronic pill container. 
 
Figure 4. Funnel plot of Standard Error by Log odds ratio 
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